The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease

Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of neurology 2021-05, Vol.28 (5), p.1557-1565
Hauptverfasser: Zimmermann, Milan, Köhler, Leonie, Kovarova, Marketa, Lerche, Stefanie, Schulte, Claudia, Wurster, Isabel, Machetanz, Gerrit, Deuschle, Christian, Hauser, Ann‐Kathrin, Gasser, Thomas, Berg, Daniela, Schleicher, Erwin, Maetzler, Walter, Brockmann, Kathrin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1565
container_issue 5
container_start_page 1557
container_title European journal of neurology
container_volume 28
creator Zimmermann, Milan
Köhler, Leonie
Kovarova, Marketa
Lerche, Stefanie
Schulte, Claudia
Wurster, Isabel
Machetanz, Gerrit
Deuschle, Christian
Hauser, Ann‐Kathrin
Gasser, Thomas
Berg, Daniela
Schleicher, Erwin
Maetzler, Walter
Brockmann, Kathrin
description Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene. Methods We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings. Results PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale. Conclusions Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD. Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.
doi_str_mv 10.1111/ene.14733
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478588163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478588163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</originalsourceid><addsrcrecordid>eNp1kc9uEzEQhy1ERdLAgRdAlrjAYRP_XXuPqAoUERUO5bxy1uPEYXcd7F1Q3osn6JPVYdsekBhZGh8-fZr5DUKvKVnSXCvoYUmF4vwZmlNR6oJyTp_nP5e0kJTQGbpM6UAIYYqRF2jGuRCVIGSOuts94Db0O_jlhxPeZRX-0oZhH7DpLfZDwg1E2MaQjr43LXbt6C0-xjCA78_d-RYSNvnhLljvPETsQsTfTPzh-xT6uz8JW5_AJHiJLpxpE7x66Av0_eP69uq62Hz99Pnqw6ZouNa8KIWuNDNalFIJKbnk4CxxumFGyaqRsKXQKAWSW8e4ZJqrLWGlNVZqbVnFF-jd5M3z_RwhDXXnUwNta3oIY6qZUDqjtOQZffsPeghjzJtmSlJWlkpUZabeT1STg0gRXH2MvjPxVFNSn29Q5-DqvzfI7JsH47jtwD6Rj6FnYDUBv3N0p_-b6vXNelLeA3HjkH8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512667496</pqid></control><display><type>article</type><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</creator><creatorcontrib>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</creatorcontrib><description>Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene. Methods We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings. Results PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale. Conclusions Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD. Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.14733</identifier><identifier>PMID: 33449400</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Aging ; Biomarkers ; Cerebrospinal fluid ; Cognitive ability ; Fibroblast growth factor 23 ; Fibroblasts ; Genetic diversity ; genetic modifier ; Genetic variability ; Genetic variance ; Genotyping ; Growth factors ; Haplotypes ; Health risks ; Klotho ; Klotho protein ; Longevity ; longevity genes ; Metabolites ; Movement disorders ; Neurodegenerative diseases ; Parkinson's disease ; Parkinson´s disease ; Phenotypes ; Proteins ; Subgroups ; Vitamin D</subject><ispartof>European journal of neurology, 2021-05, Vol.28 (5), p.1557-1565</ispartof><rights>2021 The Authors. published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2021 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</citedby><cites>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</cites><orcidid>0000-0001-7066-7749 ; 0000-0003-0157-5722</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.14733$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.14733$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33449400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimmermann, Milan</creatorcontrib><creatorcontrib>Köhler, Leonie</creatorcontrib><creatorcontrib>Kovarova, Marketa</creatorcontrib><creatorcontrib>Lerche, Stefanie</creatorcontrib><creatorcontrib>Schulte, Claudia</creatorcontrib><creatorcontrib>Wurster, Isabel</creatorcontrib><creatorcontrib>Machetanz, Gerrit</creatorcontrib><creatorcontrib>Deuschle, Christian</creatorcontrib><creatorcontrib>Hauser, Ann‐Kathrin</creatorcontrib><creatorcontrib>Gasser, Thomas</creatorcontrib><creatorcontrib>Berg, Daniela</creatorcontrib><creatorcontrib>Schleicher, Erwin</creatorcontrib><creatorcontrib>Maetzler, Walter</creatorcontrib><creatorcontrib>Brockmann, Kathrin</creatorcontrib><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene. Methods We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings. Results PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale. Conclusions Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD. Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</description><subject>Aging</subject><subject>Biomarkers</subject><subject>Cerebrospinal fluid</subject><subject>Cognitive ability</subject><subject>Fibroblast growth factor 23</subject><subject>Fibroblasts</subject><subject>Genetic diversity</subject><subject>genetic modifier</subject><subject>Genetic variability</subject><subject>Genetic variance</subject><subject>Genotyping</subject><subject>Growth factors</subject><subject>Haplotypes</subject><subject>Health risks</subject><subject>Klotho</subject><subject>Klotho protein</subject><subject>Longevity</subject><subject>longevity genes</subject><subject>Metabolites</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson's disease</subject><subject>Parkinson´s disease</subject><subject>Phenotypes</subject><subject>Proteins</subject><subject>Subgroups</subject><subject>Vitamin D</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc9uEzEQhy1ERdLAgRdAlrjAYRP_XXuPqAoUERUO5bxy1uPEYXcd7F1Q3osn6JPVYdsekBhZGh8-fZr5DUKvKVnSXCvoYUmF4vwZmlNR6oJyTp_nP5e0kJTQGbpM6UAIYYqRF2jGuRCVIGSOuts94Db0O_jlhxPeZRX-0oZhH7DpLfZDwg1E2MaQjr43LXbt6C0-xjCA78_d-RYSNvnhLljvPETsQsTfTPzh-xT6uz8JW5_AJHiJLpxpE7x66Av0_eP69uq62Hz99Pnqw6ZouNa8KIWuNDNalFIJKbnk4CxxumFGyaqRsKXQKAWSW8e4ZJqrLWGlNVZqbVnFF-jd5M3z_RwhDXXnUwNta3oIY6qZUDqjtOQZffsPeghjzJtmSlJWlkpUZabeT1STg0gRXH2MvjPxVFNSn29Q5-DqvzfI7JsH47jtwD6Rj6FnYDUBv3N0p_-b6vXNelLeA3HjkH8</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Zimmermann, Milan</creator><creator>Köhler, Leonie</creator><creator>Kovarova, Marketa</creator><creator>Lerche, Stefanie</creator><creator>Schulte, Claudia</creator><creator>Wurster, Isabel</creator><creator>Machetanz, Gerrit</creator><creator>Deuschle, Christian</creator><creator>Hauser, Ann‐Kathrin</creator><creator>Gasser, Thomas</creator><creator>Berg, Daniela</creator><creator>Schleicher, Erwin</creator><creator>Maetzler, Walter</creator><creator>Brockmann, Kathrin</creator><general>John Wiley &amp; Sons, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7066-7749</orcidid><orcidid>https://orcid.org/0000-0003-0157-5722</orcidid></search><sort><creationdate>202105</creationdate><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><author>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aging</topic><topic>Biomarkers</topic><topic>Cerebrospinal fluid</topic><topic>Cognitive ability</topic><topic>Fibroblast growth factor 23</topic><topic>Fibroblasts</topic><topic>Genetic diversity</topic><topic>genetic modifier</topic><topic>Genetic variability</topic><topic>Genetic variance</topic><topic>Genotyping</topic><topic>Growth factors</topic><topic>Haplotypes</topic><topic>Health risks</topic><topic>Klotho</topic><topic>Klotho protein</topic><topic>Longevity</topic><topic>longevity genes</topic><topic>Metabolites</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson's disease</topic><topic>Parkinson´s disease</topic><topic>Phenotypes</topic><topic>Proteins</topic><topic>Subgroups</topic><topic>Vitamin D</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimmermann, Milan</creatorcontrib><creatorcontrib>Köhler, Leonie</creatorcontrib><creatorcontrib>Kovarova, Marketa</creatorcontrib><creatorcontrib>Lerche, Stefanie</creatorcontrib><creatorcontrib>Schulte, Claudia</creatorcontrib><creatorcontrib>Wurster, Isabel</creatorcontrib><creatorcontrib>Machetanz, Gerrit</creatorcontrib><creatorcontrib>Deuschle, Christian</creatorcontrib><creatorcontrib>Hauser, Ann‐Kathrin</creatorcontrib><creatorcontrib>Gasser, Thomas</creatorcontrib><creatorcontrib>Berg, Daniela</creatorcontrib><creatorcontrib>Schleicher, Erwin</creatorcontrib><creatorcontrib>Maetzler, Walter</creatorcontrib><creatorcontrib>Brockmann, Kathrin</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zimmermann, Milan</au><au>Köhler, Leonie</au><au>Kovarova, Marketa</au><au>Lerche, Stefanie</au><au>Schulte, Claudia</au><au>Wurster, Isabel</au><au>Machetanz, Gerrit</au><au>Deuschle, Christian</au><au>Hauser, Ann‐Kathrin</au><au>Gasser, Thomas</au><au>Berg, Daniela</au><au>Schleicher, Erwin</au><au>Maetzler, Walter</au><au>Brockmann, Kathrin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2021-05</date><risdate>2021</risdate><volume>28</volume><issue>5</issue><spage>1557</spage><epage>1565</epage><pages>1557-1565</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><abstract>Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene. Methods We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings. Results PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale. Conclusions Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD. Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33449400</pmid><doi>10.1111/ene.14733</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7066-7749</orcidid><orcidid>https://orcid.org/0000-0003-0157-5722</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1351-5101
ispartof European journal of neurology, 2021-05, Vol.28 (5), p.1557-1565
issn 1351-5101
1468-1331
language eng
recordid cdi_proquest_miscellaneous_2478588163
source Wiley Online Library Journals Frontfile Complete
subjects Aging
Biomarkers
Cerebrospinal fluid
Cognitive ability
Fibroblast growth factor 23
Fibroblasts
Genetic diversity
genetic modifier
Genetic variability
Genetic variance
Genotyping
Growth factors
Haplotypes
Health risks
Klotho
Klotho protein
Longevity
longevity genes
Metabolites
Movement disorders
Neurodegenerative diseases
Parkinson's disease
Parkinson´s disease
Phenotypes
Proteins
Subgroups
Vitamin D
title The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A16%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20longevity%20gene%20Klotho%20and%20its%20cerebrospinal%20fluid%20protein%20profiles%20as%20a%20modifier%20for%20Parkinson%C2%B4s%20disease&rft.jtitle=European%20journal%20of%20neurology&rft.au=Zimmermann,%20Milan&rft.date=2021-05&rft.volume=28&rft.issue=5&rft.spage=1557&rft.epage=1565&rft.pages=1557-1565&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.14733&rft_dat=%3Cproquest_cross%3E2478588163%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512667496&rft_id=info:pmid/33449400&rfr_iscdi=true